STAT News

STAT+: AstraZeneca invests $2 billion in Summit Therapeutics

AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.

By STAT News

1 min read
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights